Catalent Inc Stock News

Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.

Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.

The S&P 500 faces strong resistance up to 4200, writes Lawrence McMillan.

After a 54% rise year-to-date, at the current levels, Catalent stock (NYSE: CTLT), a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, has little room f

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executi

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Investing in large-cap stocks is considered one of the best ways to invest in the stock market.

Bank stocks were hit hard, as investors braced for a longer cycle of interest rate increases. Electric vehicle makers also stumbled.

S&P 500 has been under pressure since early February's false breakout, writes Lawrence McMillan.

February wasn't a great month for the S&P 500. But it still presented angles to nearly double your money with stocks in just two months.

S&P 500's support is at 3900, then 3760 -- the December 2022 low, writes Lawrence McMillan.

Markets traded lower during Friday’s pre-market session following the Bureau of Economic Analysis report on a 5.4% increase in the personal consumption expenditures (PCE) price index for the month o

Options on Catalent, Qualtrics International and National Instruments could have upside.

The shares did exceptionally well considering the company had a ho-hum quarter.